Shinji Ohno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shinji Ohno has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Masakazu Toi
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
10 shared publications - Hiroji Iwata
Department of Advanced Clinical Research and Development, Nagoya City University, Nagoya, Japan
8 shared publications - Norikazu Masuda
Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
8 shared publications - Reiki Nishimura
Kumamoto Shinto General Hospital, Kumamoto, Japan
7 shared publications Katsumasa Kuroi
Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
5 shared publicationsShoshu Mitsuyama
4 shared publications
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 599
Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16).
599 Background: The presence of tumor-infiltrating lymphocytes (TILs) is associated with better outcomes in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) patients who are treated with adjuvant or neoadjuvant trastuzumab-based systemic therapy. Precise subset analysis of TILs is important to understand the role of TILs in the breast tumor microenvironment. We examined the correlation between TILs and treatment outcomes of neoadjuvant dual-HER2 blockage therapy with paclitaxel in HER2-positive EBC. Our aim was to achieve a robust understanding of the predictive value of neuropilin-1 (NRP1), an active CD4 T cell marker, and FOXP3, a well-known regulatory T cell marker, on TILs. Methods: The NeoLath study is a randomized, phase II, five-arm study evaluating the efficacy and safety of lapatinib and trastuzumab followed by lapatinib and trastuzumab plus weekly paclitaxel with or without prolongation of anti-HER2 therapy prior to chemotherapy (18 weeks vs. 6 weeks). The primary endpoint was the comprehensive pathological complete response (pCR) rate. We evaluated the %TILs, %NRP1/TILs and %FOXP3/TILs using core biopsy sections taken at diagnosis, and in surgical specimens after dual HER2 blockage therapy in the prospectively defined, retrospective analysis. Results: A total of 222 tumor samples from 74 patients were used for the present analysis. The mean level of TILs was 20.0% and pCR rate was 56.8%. Univariate analysis showed that %TILs and %NRP1/TILs were associated with pCR and multivariate analysis showed that %NRP1/TILs was significantly associated with pCR (adjusted odds ratio, 1.08 [95% CI, 1.04–1.13]; P < .0001) (table). Conclusions: In addition to TIL evaluation, analysis of NRP1 expression of TILs is important to explore prognosis in HER2-positive EBC patients who are treated with neoadjuvant dual-HER2 blockage therapy for pCR. Clinical trial information: 000007576.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 599
Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16).
599 Background: The presence of tumor-infiltrating lymphocytes (TILs) is associated with better outcomes in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) patients who are treated with adjuvant or neoadjuvant trastuzumab-based systemic therapy. Precise subset analysis of TILs is important to understand the role of TILs in the breast tumor microenvironment. We examined the correlation between TILs and treatment outcomes of neoadjuvant dual-HER2 blockage therapy with paclitaxel in HER2-positive EBC. Our aim was to achieve a robust understanding of the predictive value of neuropilin-1 (NRP1), an active CD4 T cell marker, and FOXP3, a well-known regulatory T cell marker, on TILs. Methods: The NeoLath study is a randomized, phase II, five-arm study evaluating the efficacy and safety of lapatinib and trastuzumab followed by lapatinib and trastuzumab plus weekly paclitaxel with or without prolongation of anti-HER2 therapy prior to chemotherapy (18 weeks vs. 6 weeks). The primary endpoint was the comprehensive pathological complete response (pCR) rate. We evaluated the %TILs, %NRP1/TILs and %FOXP3/TILs using core biopsy sections taken at diagnosis, and in surgical specimens after dual HER2 blockage therapy in the prospectively defined, retrospective analysis. Results: A total of 222 tumor samples from 74 patients were used for the present analysis. The mean level of TILs was 20.0% and pCR rate was 56.8%. Univariate analysis showed that %TILs and %NRP1/TILs were associated with pCR and multivariate analysis showed that %NRP1/TILs was significantly associated with pCR (adjusted odds ratio, 1.08 [95% CI, 1.04–1.13]; P < .0001) (table). Conclusions: In addition to TIL evaluation, analysis of NRP1 expression of TILs is important to explore prognosis in HER2-positive EBC patients who are treated with neoadjuvant dual-HER2 blockage therapy for pCR. Clinical trial information: 000007576.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 2527
Overall survival of participants compared to non-participants in a randomized-controlled trial (SELECT BC): A prospective cohort study.
2527 Background: Whether participation in a randomized-controlled trial provides benefits to patients is controversial. Some studies have showed that participants have longer prognosis than non-participants. However, in such studies, underlying bias always exists, such as patient condition, patient selection by physicians, and differences in the care provided. Therefore, to minimize such bias, we enrolled non-participants at the time of patient recruitment for a randomized-controlled trial, and prospectively compared the prognoses of participants and non-participants. Methods: This was a prospective cohort study accompanying the “SELection of Effective ChemoTherapy for Breast Cancer” (SELECT BC) study, which compared S-1 and taxane as first-line treatment for metastatic breast cancer and reported the non-inferiority of S-1 with respect to overall survival. Prognoses of trial participants and non-participants were compared. The endpoint was overall survival [Lancet Oncol 17:90-98, 2016]. All patients met the eligibility criteria set for SELECT BC. Results: From August 2009, when this study started, to July 2010, 228 patients were enrolled in SELECT BC, while 65 patients were registered as non-participants in this study. The median follow-up period was 32.5 months. The median overall survival of participants (36.8 months) was longer than that of non-participants (25.2 months) (hazard ratio [HR]: 1.48; 95% confidential interval [CI]: 1.06-2.07; p = 0.023). Standard chemotherapy was administered to 48 non-participants (74%); 34 (52%) of them received standard taxane regimen or S-1, which was to be administered if they participated in the trial. However, the median overall survival of these 34 patients (22.0 months) was shorter than that of the trial participants (36.8 months) (HR: 2.03; 95% CI: 1.35-3.06; p = 0.0007). Conclusions: Randomized-controlled trial participants had longer overall survival than non-participants. Several factors, such as mental status, relationship between physicians and patients, or difficulties in receiving the recommended treatment could have influenced the prognosis. Clinical trial information: 000020645.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 2527
Overall survival of participants compared to non-participants in a randomized-controlled trial (SELECT BC): A prospective cohort study.
2527 Background: Whether participation in a randomized-controlled trial provides benefits to patients is controversial. Some studies have showed that participants have longer prognosis than non-participants. However, in such studies, underlying bias always exists, such as patient condition, patient selection by physicians, and differences in the care provided. Therefore, to minimize such bias, we enrolled non-participants at the time of patient recruitment for a randomized-controlled trial, and prospectively compared the prognoses of participants and non-participants. Methods: This was a prospective cohort study accompanying the “SELection of Effective ChemoTherapy for Breast Cancer” (SELECT BC) study, which compared S-1 and taxane as first-line treatment for metastatic breast cancer and reported the non-inferiority of S-1 with respect to overall survival. Prognoses of trial participants and non-participants were compared. The endpoint was overall survival [Lancet Oncol 17:90-98, 2016]. All patients met the eligibility criteria set for SELECT BC. Results: From August 2009, when this study started, to July 2010, 228 patients were enrolled in SELECT BC, while 65 patients were registered as non-participants in this study. The median follow-up period was 32.5 months. The median overall survival of participants (36.8 months) was longer than that of non-participants (25.2 months) (hazard ratio [HR]: 1.48; 95% confidential interval [CI]: 1.06-2.07; p = 0.023). Standard chemotherapy was administered to 48 non-participants (74%); 34 (52%) of them received standard taxane regimen or S-1, which was to be administered if they participated in the trial. However, the median overall survival of these 34 patients (22.0 months) was shorter than that of the trial participants (36.8 months) (HR: 2.03; 95% CI: 1.35-3.06; p = 0.0007). Conclusions: Randomized-controlled trial participants had longer overall survival than non-participants. Several factors, such as mental status, relationship between physicians and patients, or difficulties in receiving the recommended treatment could have influenced the prognosis. Clinical trial information: 000020645.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , TPS636
PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.
TPS636 Background: Combination of pertuzumab (Pmab) with trastuzumab (Tmab) has dramatically improved patients’ outcomes compared to Tmab as 1st line therapy in HER2-positive (+ve) locally advanced (LA)/metastatic breast cancer (MBC). However, it is unclear whether reexposure to this dual HER2-blockade is more effective than conventional treatment in HER2+ve LA/MBC patients previously receiving Pmab, Tmab, and chemotherapy (CT). Methods: Trial design: PRECIOUS (NCT02514681) is a multicenter randomized open-label phase III study enrolling HER2+ve LA/MBC patients pretreated with Pmab, Tmab, and CT. Patients are randomized 1:1 to receive CT of physician’s choice (docetaxel, paclitaxel, nab-paclitaxel, vinorelbine, or eribulin) plus Tmab with or without Pmab. Eligibility criteria: Patients received Pmab, Tmab, and CT for HER2+ve LA/MBC as 1st and/or 2nd line anti-HER2-containing CT. The latest regimen before enrollment does not include Pmab. The number of previous CT regimens for LA/MBC does not exceed three. Aims: The primary endpoint is investigator-assessed progression-free survival (PFS). Secondary endpoints include independent reviewer-assessed PFS, PFS in patients treated with T-DM1 as the latest regimen, response rate, duration of response, overall survival, safety, and patient-reported outcome. Translational researches using blood samples are also planned to find prognostic and predictive markers for patients receiving anti-HER2 treatment. Statistics: PFS between control arm (Tmab and CT) and experimental arm (Pmab, Tmab, and CT) will be compared using a log-rank test. Three-hundred and seventy patients will be enrolled that allow the observation of 325 events for 80% power to detect a hazard ratio of 0.739 at one-side 5% level of significance. Accrual status: Recruitment began in August 2015 and is expected to be completed in July 2018 in Japan. Clinical trial information: NCT02514681.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , TPS636
PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.
TPS636 Background: Combination of pertuzumab (Pmab) with trastuzumab (Tmab) has dramatically improved patients’ outcomes compared to Tmab as 1st line therapy in HER2-positive (+ve) locally advanced (LA)/metastatic breast cancer (MBC). However, it is unclear whether reexposure to this dual HER2-blockade is more effective than conventional treatment in HER2+ve LA/MBC patients previously receiving Pmab, Tmab, and chemotherapy (CT). Methods: Trial design: PRECIOUS (NCT02514681) is a multicenter randomized open-label phase III study enrolling HER2+ve LA/MBC patients pretreated with Pmab, Tmab, and CT. Patients are randomized 1:1 to receive CT of physician’s choice (docetaxel, paclitaxel, nab-paclitaxel, vinorelbine, or eribulin) plus Tmab with or without Pmab. Eligibility criteria: Patients received Pmab, Tmab, and CT for HER2+ve LA/MBC as 1st and/or 2nd line anti-HER2-containing CT. The latest regimen before enrollment does not include Pmab. The number of previous CT regimens for LA/MBC does not exceed three. Aims: The primary endpoint is investigator-assessed progression-free survival (PFS). Secondary endpoints include independent reviewer-assessed PFS, PFS in patients treated with T-DM1 as the latest regimen, response rate, duration of response, overall survival, safety, and patient-reported outcome. Translational researches using blood samples are also planned to find prognostic and predictive markers for patients receiving anti-HER2 treatment. Statistics: PFS between control arm (Tmab and CT) and experimental arm (Pmab, Tmab, and CT) will be compared using a log-rank test. Three-hundred and seventy patients will be enrolled that allow the observation of 325 events for 80% power to detect a hazard ratio of 0.739 at one-side 5% level of significance. Accrual status: Recruitment began in August 2015 and is expected to be completed in July 2018 in Japan. Clinical trial information: NCT02514681.
- Open Access
- 16 March 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-9
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy
Neoadjuvant endocrine therapy (NAE) has been employed to improve surgical outcomes for hormone receptor-positive breast cancers in postmenopausal women. Endocrine responsiveness is estimated by expressions of hormone receptors, but its heterogeneity has been recognized. Autophagy is an evolutionally conserved process associated with cell survival and cell death and has been implicated in cancer treatment. In order to examine the possible association between autophagy and response to endocrine therapy, we evaluated the status of autophagy-associated markers, beclin 1 and LC3, and apoptosis-associated markers, TUNEL and M30, in pre- and post-treatment specimens from 71 patients in a multicenter prospective study of neoadjuvant exemestane (JFMC34-0601). Immunoreactivity of the autophagy-associated markers, beclin 1 and LC3, in carcinoma cells increased in 14 % and 52 % of the patients, respectively, following the exemestane treatment. These increases were statistically significant (beclin 1, p = 0.016, N = 49; LC3, p < 0.0001, N = 33). The status of M30 immunoreactivity decreased (p = 0.008, N = 47) and TUNEL remained unchanged (N = 53). In addition, tumors with pre-treatment stromal beclin 1 immunoreactivity revealed poor clinical and pathological responses compared with those without stromal beclin 1 immunoreactivity (25 % vs 67 % for clinical response, p = 0.011, N = 51; 0 % vs 41 % for pathological response, p = 0.0081, N = 49). Tumors with positive pre-treatment stromal beclin 1 had a higher baseline Ki-67 labeling index (both hot spot and overall average) than those without (p = 0.042 and 0.0075, respectively, N = 53). Results of logistic regression analyses revealed that stromal beclin 1 was a predictor for clinical and pathological responses while ER, PR, Ki-67, and stromal LC3 expressions were not. Results of our present study demonstrated that beclin 1 and LC3 immunoreactivity increased in carcinoma cells following exemestane treatment and that the status of pre-treatment stromal beclin 1 is associated with higher carcinoma cell proliferation and poor clinical and pathological responses to NAE. UMIN C000000345 (2006/03/06)
- 16 March 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-9
Open AccessClinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy
Neoadjuvant endocrine therapy (NAE) has been employed to improve surgical outcomes for hormone receptor-positive breast cancers in postmenopausal women. Endocrine responsiveness is estimated by expressions of hormone receptors, but its heterogeneity has been recognized. Autophagy is an evolutionally conserved process associated with cell survival and cell death and has been implicated in cancer treatment. In order to examine the possible association between autophagy and response to endocrine therapy, we evaluated the status of autophagy-associated markers, beclin 1 and LC3, and apoptosis-associated markers, TUNEL and M30, in pre- and post-treatment specimens from 71 patients in a multicenter prospective study of neoadjuvant exemestane (JFMC34-0601). Immunoreactivity of the autophagy-associated markers, beclin 1 and LC3, in carcinoma cells increased in 14 % and 52 % of the patients, respectively, following the exemestane treatment. These increases were statistically significant (beclin 1, p = 0.016, N = 49; LC3, p < 0.0001, N = 33). The status of M30 immunoreactivity decreased (p = 0.008, N = 47) and TUNEL remained unchanged (N = 53). In addition, tumors with pre-treatment stromal beclin 1 immunoreactivity revealed poor clinical and pathological responses compared with those without stromal beclin 1 immunoreactivity (25 % vs 67 % for clinical response, p = 0.011, N = 51; 0 % vs 41 % for pathological response, p = 0.0081, N = 49). Tumors with positive pre-treatment stromal beclin 1 had a higher baseline Ki-67 labeling index (both hot spot and overall average) than those without (p = 0.042 and 0.0075, respectively, N = 53). Results of logistic regression analyses revealed that stromal beclin 1 was a predictor for clinical and pathological responses while ER, PR, Ki-67, and stromal LC3 expressions were not. Results of our present study demonstrated that beclin 1 and LC3 immunoreactivity increased in carcinoma cells following exemestane treatment and that the status of pre-treatment stromal beclin 1 is associated with higher carcinoma cell proliferation and poor clinical and pathological responses to NAE. UMIN C000000345 (2006/03/06)
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii78
Predictions of pathological response after preoperative chemotherapy plus trastuzumab in HER2-positive breast cancer
Purpose: This study aimed to develop a mathematical model to predict pathological treatment response after preoperative chemotherapy plus trastuzumab.
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii78
Predictions of pathological response after preoperative chemotherapy plus trastuzumab in HER2-positive breast cancer
Purpose: This study aimed to develop a mathematical model to predict pathological treatment response after preoperative chemotherapy plus trastuzumab.
- 14 March 2015
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (4) , 723-724
Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients
- 14 March 2015
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (4) , 723-724
Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients
- 10 February 2015
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (4) , 709-722
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
Previous large trials with trastuzumab (TZM) showed improved outcome in patients with HER2-positive early-stage breast cancer. However, the efficacy and safety of TZM in Japanese patients have not been fully evaluated. We have therefore conducted an observational study in Japan. This was a retrospective and a prospective observational study in which data on women with histologically confirmed HER2-positive invasive breast cancer who received TZM for stage I–IIIC disease were collected from 56 institutions that participated in the Japan Breast Cancer Research Group and the efficacy of each treatment regimen analyzed. A total of 2,024 patients treated between July 2009 and June 2011 were initially enrolled in this study; in August 2013, the patient cohort comprised 2,009 patients. Of these, 142 (7.5 %) were aged ≥70 years, 1,097 (58.1 %) had clinically node-negative (cN0) breast cancer, and 883 (47.4 %) were estrogen receptor-positive. Treatment options were neoadjuvant therapy (662 patients) and adjuvant therapy with TZM (1,228 patients). Three-year overall survival (OS) rates in the entire cohort and in the neoadjuvant and adjuvant cohorts, respectively, were 98.9 [95 % confidence interval (CI) 98.2–99.3], 98.3 (95 % CI 96.8–99.1 %), and 99.2 % (95 % CI 98.4–99.6), respectively. Three-year disease-free survival (DFS) rates in the entire cohort and in the neoadjuvant and adjuvant cohorts, respectively were 94.2 (95 % CI 93.0–95.2), 94.8 (95 % CI 93.0–95.9), and 93.1 (95 % CI 90.7–94.9 %), respectively. Multivariate analysis showed that age and nodal status negatively correlated with DFS. Age was the only factor which correlated with OS rate. Adverse events (AEs) associated with TZM and grade 3/4 AEs were reported in 356 (18.8 %) and 14 (0.6 %) patients, respectively. Grade 3/4 cardiac toxicities were reported in 11 patients. Based on data from our patient cohort of Japanese women with HER2-positive early-stage breast cancer, the efficacy and safety of systemic therapy with TZM are comparable to data from previously conducted large trials. Progress in anti-HER2 therapy for patients aged ≥70 years who have a poorer prognosis is needed.
- 10 February 2015
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (4) , 709-722
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
Previous large trials with trastuzumab (TZM) showed improved outcome in patients with HER2-positive early-stage breast cancer. However, the efficacy and safety of TZM in Japanese patients have not been fully evaluated. We have therefore conducted an observational study in Japan. This was a retrospective and a prospective observational study in which data on women with histologically confirmed HER2-positive invasive breast cancer who received TZM for stage I–IIIC disease were collected from 56 institutions that participated in the Japan Breast Cancer Research Group and the efficacy of each treatment regimen analyzed. A total of 2,024 patients treated between July 2009 and June 2011 were initially enrolled in this study; in August 2013, the patient cohort comprised 2,009 patients. Of these, 142 (7.5 %) were aged ≥70 years, 1,097 (58.1 %) had clinically node-negative (cN0) breast cancer, and 883 (47.4 %) were estrogen receptor-positive. Treatment options were neoadjuvant therapy (662 patients) and adjuvant therapy with TZM (1,228 patients). Three-year overall survival (OS) rates in the entire cohort and in the neoadjuvant and adjuvant cohorts, respectively, were 98.9 [95 % confidence interval (CI) 98.2–99.3], 98.3 (95 % CI 96.8–99.1 %), and 99.2 % (95 % CI 98.4–99.6), respectively. Three-year disease-free survival (DFS) rates in the entire cohort and in the neoadjuvant and adjuvant cohorts, respectively were 94.2 (95 % CI 93.0–95.2), 94.8 (95 % CI 93.0–95.9), and 93.1 (95 % CI 90.7–94.9 %), respectively. Multivariate analysis showed that age and nodal status negatively correlated with DFS. Age was the only factor which correlated with OS rate. Adverse events (AEs) associated with TZM and grade 3/4 AEs were reported in 356 (18.8 %) and 14 (0.6 %) patients, respectively. Grade 3/4 cardiac toxicities were reported in 11 patients. Based on data from our patient cohort of Japanese women with HER2-positive early-stage breast cancer, the efficacy and safety of systemic therapy with TZM are comparable to data from previously conducted large trials. Progress in anti-HER2 therapy for patients aged ≥70 years who have a poorer prognosis is needed.
- Open Access
- 15 March 2013
- Published by Springer Nature in Breast Cancer
- Vol. 20 (4) , 291-295
An overview of the Japan Breast Cancer Research Group (JBCRG) activities
The purpose of this article is to describe the current status and future perspectives of the Japan Breast Cancer Research Group (JBCRG). The JBCRG was organized in 2002, with the following purpose: to plan and promote clinical trials and basic research in breast cancer domestically and multilaterally; to conduct research and surveys on domestic and foreign information on medical care for breast cancer and to diffuse and highlight such information; to improve and promote clinical technologies for breast cancer; to act as an intermediary to liaise and strengthen alliances with affiliated organizations; and, to contribute to the public welfare by improving outcomes in breast cancer. The clinical trials are led by doctors/investigators in the JBCRG. And the purpose is to establish standard treatment for patients and provide substantial evidence. The JBCRG implements international collaboration in some researches/studies. As of January 2012, fourteen trials have been closed and nine are open to recruitment.
- 15 March 2013
- Published by Springer Nature in Breast Cancer
- Vol. 20 (4) , 291-295
Open AccessAn overview of the Japan Breast Cancer Research Group (JBCRG) activities
The purpose of this article is to describe the current status and future perspectives of the Japan Breast Cancer Research Group (JBCRG). The JBCRG was organized in 2002, with the following purpose: to plan and promote clinical trials and basic research in breast cancer domestically and multilaterally; to conduct research and surveys on domestic and foreign information on medical care for breast cancer and to diffuse and highlight such information; to improve and promote clinical technologies for breast cancer; to act as an intermediary to liaise and strengthen alliances with affiliated organizations; and, to contribute to the public welfare by improving outcomes in breast cancer. The clinical trials are led by doctors/investigators in the JBCRG. And the purpose is to establish standard treatment for patients and provide substantial evidence. The JBCRG implements international collaboration in some researches/studies. As of January 2012, fourteen trials have been closed and nine are open to recruitment.
- Open Access
- 31 October 2012
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (5) , R140
Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer
Introduction: Identification of useful markers associated with poor prognosis in breast cancer patients is critically needed. We previously showed that expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful to predict distant metastasis in gastric cancer patients. However, expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood of breast cancer patients has not yet been studied. Methods: Real-time reverse transcriptase-PCR was used to analyze vascular endothelial growth factor receptor-1 mRNA expression status with respect to various clinical parameters in 515 patients with breast cancer and 25 controls. Results: Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood was higher in breast cancer patients than in controls. Increased vascular endothelial growth factor receptor-1 mRNA expression was associated with large tumor size, lymph node metastasis and clinical stage. Patients with high vascular endothelial growth factor receptor-1 mRNA expression also experienced a poorer survival rate than those with low expression levels, including those patients with triple-negative type and luminal-HER2(-) type disease. Conclusions: Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful for prediction of poor prognosis in breast cancer, especially in patients with triple-negative type and luminal-HER2(-) type disease.
- 31 October 2012
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (5) , R140
Open AccessVascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer
Introduction: Identification of useful markers associated with poor prognosis in breast cancer patients is critically needed. We previously showed that expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful to predict distant metastasis in gastric cancer patients. However, expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood of breast cancer patients has not yet been studied. Methods: Real-time reverse transcriptase-PCR was used to analyze vascular endothelial growth factor receptor-1 mRNA expression status with respect to various clinical parameters in 515 patients with breast cancer and 25 controls. Results: Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood was higher in breast cancer patients than in controls. Increased vascular endothelial growth factor receptor-1 mRNA expression was associated with large tumor size, lymph node metastasis and clinical stage. Patients with high vascular endothelial growth factor receptor-1 mRNA expression also experienced a poorer survival rate than those with low expression levels, including those patients with triple-negative type and luminal-HER2(-) type disease. Conclusions: Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful for prediction of poor prognosis in breast cancer, especially in patients with triple-negative type and luminal-HER2(-) type disease.
- 1 September 2012
- p. 232-7
[Clinical implementation of the immunohistochemical intrinsic subtypes of breast cancer].
- 1 September 2012
- p. 232-7
[Clinical implementation of the immunohistochemical intrinsic subtypes of breast cancer].